N-Butyl-α-methyl-succinimid | 90608-76-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Butyl-α-methyl-succinimid
• 英文别名: N-n-Butyl-2-methylsuccinimid；1-butyl-3-methyl-pyrrolidine-2,5-dione；1-Butyl-3-methylpyrrolidine-2,5-dione
• CAS: 90608-76-7
• 化学式: C₉H₁₅NO₂
• mdl: MFCD11044379
• 分子量: 169.224
• InChiKey: MAXADQYJXGNHJC-UHFFFAOYSA-N

物化性质

• 沸点：
  276.1±9.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180169256A1

  公开（公告）日：2018-06-21

  The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.

  这项发明涉及新型结合物-前药偶联物（APDCs），其中结合物与动力蛋白纺锤体抑制剂的非活性前体化合物偶联，以及抗体药物偶联物ADCs以及制备这些APDCs和ADCs的方法。
• SOLID SUPPORTED TRITHIOL COMPOUNDS FOR REMOVING HEAVY METALS FROM SOLUTION, AND FILTRATION SYSTEMS UTILIZING THE COMPOUNDS
  申请人：Covalent Research Technologies, LLC

  公开号：US20160152563A1

  公开（公告）日：2016-06-02

  Solid-supported trithiol compounds are prepared. The solid-supported trithiol compounds have formula (I): in which R is a linker moiety, X is a solid support, and n≧1. The compounds of formula (I) may be incorporated into methods for removing heavy metals from solutions and into batch systems or filtration apparatus that remove heavy metals from solutions.

  制备了固相三硫化合物。该固相三硫化合物的化学式为（I）：其中R是连接基团，X是固体支持剂，n≧1。式（I）的化合物可以用于从溶液中去除重金属的方法中，并可以用于批处理系统或过滤设备中，用于从溶液中去除重金属。
• DRUG-CONJUGATES AND USES THEREOF
  申请人：Concortis Biosystems, Corp

  公开号：EP3925627A1

  公开（公告）日：2021-12-22

  In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

  一方面，提供了一种活性剂-共轭物、活性剂-共轭物的制备方法及其用途。
• Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10022453B2

  公开（公告）日：2018-07-17

  The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型抗体药物共轭物（ADCs）、这些ADCs的活性代谢物、制备这些ADCs的工艺、使用这些ADCs治疗和/或预防疾病，以及使用这些ADCs制备治疗和/或预防疾病的药物，特别是过度增殖和/或血管生成性疾病，例如癌症。这种治疗可以作为单一疗法进行，也可以与其他药物或进一步的治疗措施结合使用。
• ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP)
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160346402A1

  公开（公告）日：2016-12-01

  The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.